Amerikanische Gesellschaft für Hirudotherapie

Štátny ústav pre kontrolu liečiv — State Institute for Drug Control of Slovakia

ŠÚKL · Slovakia · europe

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Slovakia's State Institute for Drug Control — leeches fall under EU medical-device frameworks (MDR 2017/745) as implemented through Slovak national law; leech-specific national authorisation has not been independently verified by ASH.

Regulatory Profile

Agency type
national regulator
Region
europe
Country
Slovakia
Leech status
unregulated
Last ASH review
2026-05-26

Relevant Regulation Codes

  • Slovak Act No. 362/2011 on Medicinal Products and Medical Devices
  • EU Medical Device Regulation (MDR) 2017/745 — as transposed into Slovak law
  • Slovak Act No. 578/2004 on Healthcare Providers

Prescriber Requirements

  • Slovak Medical Chamber (Slovenská lekárska komora)–registered physician — order required for any biomedical device application
  • Allied health professional application under physician supervision per institutional protocol

Supply Chain & GMP

ŠÚKL registration as applicable; Slovak-language labelling required by national law. Standard cold-chain conditions; EU intra-community movement under MDR applies.

Import/Export Rules

Free movement within the EU single market under MDR; State Veterinary and Food Administration clearance for live invertebrates from non-EU origin; CITES Appendix II paperwork for Hirudo medicinalis / verbana on extra-EU import.

Reimbursement Context

General Health Insurance Company (VšZP) and other public payers may cover inpatient bundled use; outpatient hirudotherapy is generally not separately reimbursed.

ASH Editorial Notes

Leech-specific pathway not independently verified by ASH; falls under general EU MDR framework as transposed into Slovak law. ŠÚKL coordinates with EMA and other EU NCAs; whether leech-specific guidance exists has not been independently mapped by ASH.

Related Jurisdictions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.